Bone Biologics holders approve reverse split range of 1-for-2 to 1-for-10 and warrant-share issuance at annual meeting

Bone Biologics Corp

• Stockholders approved a charter amendment for a reverse split of 1-for-2 up to 1-for-10 at board discretion; vote 806,603 for vs 137,720 against.
• Approved Nasdaq Rule 5635(d) issuance of shares underlying warrants from the July 7, 2026 Securities Purchase Agreement and H.C. Wainwright engagement letter; 147,340 for, 42,233 against.
• Elected four directors — Bruce Stroever, Siddhesh Angle, Robert Gagnon and Philip Meikle — each with roughly 152,615-158,799 votes for and about 3,900 withheld.
• Ratified Weinberg & Company, P.A. as independent auditor for fiscal 2026 (898,011 for, 49,834 against); advisory say-on-pay passed 139,592 for vs 49,851 against.
• 2,011,057 shares were entitled to vote and 951,746 were present or by proxy (about 47%), with 758,866 broker non-votes on the contested proposals.